When the increased NOX1 levels in patients with GAD are evaluated together with the NOX increases observed in rats in the aforementioned studies in the hippocampus and amygdala (important areas of the brain in anxiety), we believe that further studies should be conducted on the therapeutic effect of NOX downregulators in this group. The gene discussed is NOX1; the disease is generalized anxiety disorder.